SUNNYVALE, Calif., March 5, 2015 /CNW/ -- Accuray Incorporated
(Nasdaq: ARAY) and Christie InnoMed Inc. announced today that they
have entered into sales agent agreements involving the
CyberKnife® and TomoTherapy®
System product portfolios in Canada. Under the terms of these agreements,
Christie InnoMed will be the exclusive sales agent for Accuray
products in this region.
"Christie InnoMed is a well-respected organization known for
representing high-quality, leading-edge products. By joining forces
with Christie, Accuray gains additional market coverage and
increased visibility for our precise, innovative CyberKnife and
TomoTherapy Systems," said Joshua H.
Levine, president and chief executive officer of Accuray.
"We expect that our collaboration will significantly enhance our
overall selling presence in Canada, ultimately resulting in new order
growth and increased patient access to our life-saving technologies
moving forward."
Established in 1954, Christie InnoMed has an extensive knowledge
of the Canadian radiosurgery and radiation therapy market from both
a product and customer perspective. Covering the Canadian medical
market for more than 60 years, they have established strong
relationships with clinicians and administrators in many of the
cancer centers and hospitals across the country. Under the new
agreements, Christie became eligible to act as sales agent
beginning on December 1, 2014. More
than 16 account managers with a total of over 200 years' experience
will use their industry expertise to identify and cultivate
potential customers for Accuray products. The CyberKnife and
TomoTherapy System product lines have set the standard of care for
patients requiring radiation therapy. Both systems deliver precise
doses of radiation to treat cancerous and non-cancerous tumors
throughout the body.
"We look forward to a long-term partnership with Accuray and the
chance to work with a company focused on providing solutions that
help clinicians optimize patient care," said Dr. Michel Vachon, president and chief executive
officer of Christie InnoMed Inc. "The addition of the CyberKnife
and TomoTherapy Systems complement our existing product line of
radiography imaging equipment. Our extensive market knowledge and
deep-seated customer relationships provide us with the opportunity
to have a positive impact on new order growth for these clinically
proven technologies."
About Christie InnoMed
Christie InnoMed develops, distributes, integrates and supports
technological products and solutions that improve performance of
Canadian healthcare institutions in the areas of medical imaging
and healthcare management solutions. The Christie InnoMed team
helps hospitals and clinics optimize their imaging rooms and
enhance their performance in terms of screening, diagnosis and
management. Christie InnoMed offers customers extensive technical
and clinical support to improve workflows, and optimize use of
imaging technology, thereby helping deliver the best care
possible.
About the CyberKnife® and TomoTherapy®
Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series
treatment solutions cover the entire spectrum of radiation therapy
needs. The CyberKnife M6 Series enables precise, high-quality, dose
distributions to be confidently delivered to the patient with
extreme accuracy over a minimum number of treatments, reducing side
effects and preserving patients' quality of life. The CyberKnife
System is the only robotic full-body radiosurgery system available
today. The TomoTherapy H Series efficiently enables physicians to
customize treatment plans for the entire range of radiation therapy
patients and disease types. Its innovative design enables treatment
plans to be delivered with integrated, daily CT image guidance,
enhancing accuracy and delivering highly precise,
intensity-modulated radiation for optimal sparing of healthy tissue
and critical structures.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to Accuray's selling presence
in Canada, new order growth,
patient access, clinical applications, clinical results, patient
outcomes and Accuray's leadership position in radiation oncology
innovation and technologies. Forward-looking statements are subject
to risks and uncertainties that could cause actual results to
differ materially from expectations, including but not limited to
the risks detailed under the heading "Risk Factors" in Accuray's
report on Form 10-K, filed on August 29,
2014, the company's report on Form 10-Q, filed on
November 7, 2014, the company's
report on Form 10-Q, filed on February 6,
2015, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
SOURCE Accuray Incorporated